Asthma News and Research

RSS

Asthma is a common inflammatory disease affecting the airways that leads to shortness of breath, coughing and wheezing. Symptoms range from mild to severe but are generally manageable with appropriate treatment.

Allergan settles patent litigation with Amneal related to NAMENDA XR extended release capsules

Allergan plc, today announced that its subsidiaries Forest Laboratories, LLC and Forest Laboratories Holdings, Ltd., along with Adamas Pharmaceuticals, Inc., have entered into a settlement agreement with Amneal Pharmaceuticals LLC and related companies and subsidiaries.

10 Sep 2015

Scientific Director of Life Study to present lecture at University of Leicester

Professor Carol Dezateux, Scientific Director of Life Study, will present 'Life Study: Identifying Pathways to Health in Early Life' on Thursday, September 10, as the first of a series of lectures to celebrate the 40th Anniversary of the University of Leicester Medical School.

10 Sep 2015

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States.

9 Sep 2015

Study: Wildfire smoke exposure associated with increased visits to ER for asthma

Researchers who analyzed data from the 2006-2007 wildfires in Australia found that exposure to wildfire smoke was linked to increased visits to hospital emergency departments for asthma.

9 Sep 2015

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Vernalis Therapeutics Inc., a subsidiary of Vernalis plc, today announced that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA Schedule III) is now available to adult patients and physicians in the United States.

8 Sep 2015

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

Rigel Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to Fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor which is currently in Phase 3 clinical studies in patients with chronic immune thrombocytopenic purpura (ITP).

8 Sep 2015

Scientists discover mechanism that could lead to new treatment for allergies

Most people with allergies have to take medication throughout their life: Their body "thinks" that proteins from the environment are so "strange" that they elicit an immune reaction. Until present, it was not possible to develop an efficient therapy so that the body "learns" to stop in an overreacting way.

8 Sep 2015

Penn researchers identify viral products that trigger immune response against RSV infection

Almost all human beings are exposed to the respiratory syncytial virus, or RSV, before their second birthdays. For most, the symptoms mimic those of the common cold: runny nose, coughing, sneezing, fever.

4 Sep 2015

Simple checklist to help parents determine their children’s school environment

Grassroots Environmental Education, a science-based environmental health non-profit organization based in New York, has issued a simple three-point checklist for parents of school-age children to help them determine if their child's school environment is as healthy as it can be.

4 Sep 2015

Researchers one step closer to developing asthma vaccine

Researchers at VIB (a leading life sciences institute in Flanders, Belgium) and Ghent University have successfully established a causal relationship between exposure to so-called farm dust and protection against asthma and allergies.

4 Sep 2015

Swecure receives US patent approval for preventive allergy treatment

Swecure, a research and development stage biotechnology company primarily focused on developing novel treatments for immunoregulatory diseases such as allergy, IBD and IBS, receives patent approval grant by the US Patent and Trademark Office. The invention relates to a use of bacterial superantigens for the prevention of allergy in children as well as a method for the prevention of inflammatory disorders.

1 Sep 2015

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada.

1 Sep 2015

Scientists elucidate chemical process behind eosinophilic esophagitis

Scientists from the D'Or Institute of Research and Education, the Federal University of Rio de Janeiro and the Yale University School of Medicine have elucidated the chemical process behind a mysterious gastrointestinal disease that is becoming more frequent every day: the eosinophilic esophagitis (EoE), also known as the "asthma of the esophagus".

1 Sep 2015

Researchers examine how patients handle stigma of using medical marijuana

Research recently published in Journal of Psychoactive Drugs (Routledge) examines the experiences of California residents who have been prescribed medical marijuana and the stigma they experience from public opinion. The findings indicate that the stigma of using medical marijuana may contribute to the under-treatment of those who might benefit from medical marijuana.

29 Aug 2015

UVM-led research team to study benefits of integrating behavioral health care with medical care

A University of Vermont-led research team has received approval for $18.5 million in funding to study whether patients with both medical and behavioral problems do better when their primary care physicians work in combination with behavioral health professionals including psychologists and social workers.

28 Aug 2015

Findings reveal a new way to prevent meningitis

The fungus Cryptococcus causes meningitis, a brain disease that kills about 1 million people each year — mainly those with impaired immune systems due to AIDS, cancer treatment or an organ transplant.

28 Aug 2015

Children exposed to toxic air pollutants at home more likely to have lower GPAs

A University of Texas at El Paso study on children's health has found that fourth and fifth graders who are exposed to toxic air pollutants at home are more likely to have lower GPAs.

28 Aug 2015

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).

27 Aug 2015

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Allergan plc, a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration has accepted the company's resubmission of its Supplemental Biologics License Application (sBLA) for BOTOX (onabotulinumtoxinA) for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults.

20 Aug 2015

Discovery provides new insights into how asthma may be caused

Researchers from the University of Leicester and University Hospitals of Leicester NHS Trust, working with the National Institute of Allergy and Infectious Diseases and Genentech, have discovered new insights into how asthma may be caused, by identifying three distinct groups of asthma patients characterised by the activity of different genes in an individual's airways.

20 Aug 2015

Asthma News and Research

Further Reading

Allergan settles patent litigation with Amneal related to NAMENDA XR extended release capsules

Scientific Director of Life Study to present lecture at University of Leicester

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Study: Wildfire smoke exposure associated with increased visits to ER for asthma

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

Scientists discover mechanism that could lead to new treatment for allergies

Penn researchers identify viral products that trigger immune response against RSV infection

Simple checklist to help parents determine their children’s school environment

Researchers one step closer to developing asthma vaccine

Swecure receives US patent approval for preventive allergy treatment

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Scientists elucidate chemical process behind eosinophilic esophagitis

Researchers examine how patients handle stigma of using medical marijuana

UVM-led research team to study benefits of integrating behavioral health care with medical care

Findings reveal a new way to prevent meningitis

Children exposed to toxic air pollutants at home more likely to have lower GPAs

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Discovery provides new insights into how asthma may be caused

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News